Efficacy and safety of low dose aztreonam in the treatment of moderate to severe gram-negative bacterial infections.

Abstract

One hundred and fifty-three patients with moderate to severe infections due to Gram-negative bacteria, including septicaemia (60 cases), lower respiratory tract infection (32 cases), intra-abdominal infection (40 cases) and urinary tract infection (21 cases), were treated with aztreonam 1 g every 12 h. This dosage is lower than usual. Criteria for inclusion included documented Gram-negative bacterial infections, and assessment of the severity of the disease by a scoring system for both community and hospital acquired infections. No other antibiotic active against Gram-negative bacteria was allowed. In 71 patients, in whom Gram-positive or anaerobic organisms were detected or suspected, additional agents effective against these organisms were administered. One hundred and forty-one patients (92.2%) were cured with a mean duration of treatment of 10.9 +/- 4.0 days. None of the Gram-negative bacteria initially isolated became resistant to aztreonam. Colonization, generally by a Gram-positive organism, was observed in 27 patients and superinfection in five. Aztreonam was well tolerated. This study suggests that a daily dosage of 2 g of aztreonam should be sufficient in the treatment of moderate to severe Gram-negative bacillary infections due to sensitive organisms.

• Authors: A Clergeot, D Steru, M A Rosset, C Carbon
• Journal: The Journal of antimicrobial chemotherapy (J Antimicrob Chemother) Vol. 23 Issue 5 Pg. 753-8 (May 1989) ISSN: 0305-7453 [Print] England
• PMID: 2759924 (Publication Type: Journal Article)

Chemical References

• Aztreonam

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Aztreonam (administration & dosage, therapeutic use)
• Bacterial Infections (drug therapy, microbiology)
• Female
• Gram-Negative Bacteria
• Humans
• Injections, Intravenous
• Male
• Middle Aged